AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31472684 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene panel testing for mutations including BRCA1, BRCA2, CHEK2, PALB2, and others
Number of subjects: 62
Study 31472684 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene panel testing for mutations
Number of subjects: 62
Study 31473451 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ankle mobilization at 2°/s on both legs using a dynamometer
Number of subjects: 13
Study 31473451 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 for calculating passive ankle joint stiffness
Number of subjects: 13
Study 31473451 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 for calculating passive ankle joint stiffness
Number of subjects: 13
Study 31473451 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 for calculating passive ankle joint stiffness
Number of subjects: 13
Study 31473451 — intervention group
Group type: EXPERIMENTAL
Intervention: Paretic values of passive ankle joint stiffness
Number of subjects: 13
Study 31473727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D 4000 IU/day for 6 months
Number of subjects: 85
Study 31473727 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 85
Study 31473943 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib hydrochloride (initial dose 20/30 mg/day)
Number of subjects: 0
Study 31474223 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA-guided dry weight adjustment
Number of subjects: 19
Study 31474223 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical-guided dry weight adjustment
Number of subjects: 19
Study 31474231 — intervention group
Group type: EXPERIMENTAL
Intervention: Food literacy education sessions on nutritional topics and practical activities
Number of subjects: 921
Study 31474600 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional synthetic disease-modifying antirheumatic drugs and/or tumor necrosis factor inhibitors
Number of subjects: 571
Study 31474848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex
Number of subjects: 56
Study 31474848 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training with sham stimulation
Number of subjects: 56
Study 31474848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS)
Number of subjects: 56
Study 31475295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan treatment
Number of subjects: 794
Study 31475856 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnl concentrations <5 ng/L
Number of subjects: 32837
Study 31475856 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnl concentrations <2 ng/L
Number of subjects: 32837
Study 31476851 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (BV) administered intravenously at 1.8 mg/kg every 3 weeks
Number of subjects: 33
Study 31476851 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (BV)
Number of subjects: 33
Study 31477052 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing of the T cell receptor (TCR) repertoire
Number of subjects: 0
Study 31477052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lymphocyte reaction between kidney donor and recipient
Number of subjects: 0
Study 31477052 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of TCR repertoire diversity and clonal expansion of T cells
Number of subjects: 0
Study 31477052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking of alloreactive T cell clones
Number of subjects: 0
Study 31477182 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal phalangeal braided toenail flap
Number of subjects: 29
Study 31477195 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention impairment in MDD patients
Number of subjects: 1008
Study 31477198 — intervention group
Group type: EXPERIMENTAL
Intervention: SSB intake at 5 years of age (100 ml/d increments)
Number of subjects: 555
Study 31477198 — intervention group
Group type: EXPERIMENTAL
Intervention: SSB intake at 5 years of age (categorical tertiles)
Number of subjects: 555
Study 31477198 — intervention group
Group type: EXPERIMENTAL
Intervention: SSB intake at 18 months of age
Number of subjects: 555
Study 31477457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessment in African Americans with diabetes
Number of subjects: 0
Study 31477479 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Dissection Endovascular System (covered stent graft and bare metal stent)
Number of subjects: 73
Study 31477781 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove intervention
Number of subjects: 50
Study 31477781 — intervention group
Group type: COMPARATOR
Intervention: Wood cooking
Number of subjects: 50
Study 31477906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-affinity CD19 CAR T cell therapy
Number of subjects: 0
Study 31478151 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRInt exercise program plus Botulinum neurotoxin (BoNT)
Number of subjects: 15
Study 31479702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with local therapy (stereotactic radiosurgery, surgery, or laser interstitial thermal therapy)
Number of subjects: 23
Study 31479702 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab without local therapy
Number of subjects: 23
Study 31480086 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery (90 infants) or bevacizumab (22 infants)
Number of subjects: 323
Study 31480086 — intervention group
Group type: COMPARATOR
Intervention: Untreated infants (211 infants)
Number of subjects: 323
Study 31480291 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling of gastric cancer
Number of subjects: 224
Study 31481121 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose post-transplant cyclophosphamide (14.5 mg/kg on days 3 and 4) with anti-thymocyte globulin (ATG)
Number of subjects: 239
Study 31481367 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHP Evelina London model of care
Number of subjects: 90000
Study 31481367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-methods process evaluation
Number of subjects: 90000
Study 31481367 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of routine clinical and administrative data
Number of subjects: 90000
Study 31481367 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews and focus groups with stakeholders
Number of subjects: 90000
Study 31481367 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy review
Number of subjects: 90000
Study 31481373 — intervention group
Group type: EXPERIMENTAL
Intervention: Management in low, middle, and high income countries (HICs)
Number of subjects: 0
Study 31481506 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolytic tumors
Number of subjects: 325
Study 31481506 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic classification based on glycolytic and cholesterogenic pathways
Number of subjects: 325
Study 31481511 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg twice daily for 14 days on/14 days off
Number of subjects: 41
Study 31481566 — intervention group
Group type: EXPERIMENTAL
Intervention: Antirheumatic treatments
Number of subjects: 0
Study 31481566 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status evaluation
Number of subjects: 0
Study 31481566 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities and prescribed drugs identification
Number of subjects: 0
Study 31481569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group undergoing modern revascularisation techniques
Number of subjects: 420
Study 31481569 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort
Number of subjects: 420
Study 31481569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI and frailty assessments for patients aged ≥65 years undergoing intervention
Number of subjects: 420
Study 31481633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged ICU stay (≥8 days)
Number of subjects: 674
Study 31481633 — intervention group
Group type: COMPARATOR
Intervention: Short ICU stay (<8 days)
Number of subjects: 674
Study 31481800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 55
Study 31481800 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 55
Study 31481889 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT)
Number of subjects: 140
Study 31481889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 140
Study 31481889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (COMB)
Number of subjects: 140
Study 31481889 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 140
Study 31482242 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow wavelength excitation source (805-nm laser) added to conventional neurosurgical microscope
Number of subjects: 11
Study 31482569 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (5 to 300 mg)
Number of subjects: 0
Study 31482830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) fitted intraorally at fixed 75% maximal protrusion
Number of subjects: 100
Study 31482831 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 303
Study 31482981 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary healing strategy using hydrofiber, n=4
Number of subjects: 16
Study 31482981 — intervention group
Group type: COMPARATOR
Intervention: Primary closure of the wound, n=12
Number of subjects: 16
Study 31483485 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T immunotherapy (3 biweekly infusions)
Number of subjects: 1976
Study 31483485 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T immunotherapy
Number of subjects: 1976
Study 31484461 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 646
Study 31484498 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB implementation
Number of subjects: 38078
Study 31484632 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory support at birth
Number of subjects: 145
Study 31484632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 145
Study 31484632 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-sustaining care
Number of subjects: 145
Study 31484632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause of death
Number of subjects: 145
Study 31484632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy status
Number of subjects: 145
Study 31484667 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2.CAR.15 (CD28-based construct with IL15)
Number of subjects: 0
Study 31484667 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2.CAR (CD28-based construct without IL15)
Number of subjects: 0
Study 31484667 — intervention group
Group type: COMPARATOR
Intervention: 4-1BB-based constructs
Number of subjects: 0
Study 31485239 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-INH (SC) 60 IU/kg
Number of subjects: 90
Study 31485239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31485335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact cord resuscitation
Number of subjects: 0
Study 31485335 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 0
Study 31485435 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for prostate cancer including novel therapies
Number of subjects: 3636
Study 31485435 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported quality-of-life measurement
Number of subjects: 3636
Study 31485435 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical resource utilization
Number of subjects: 3636
Study 31485435 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease status and outcome variables
Number of subjects: 3636
Study 31485982 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon cancer patients
Number of subjects: 0
Study 31485982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal cancer patients
Number of subjects: 0
Study 31486377 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 851
Study 31486377 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 851
Study 31486377 — intervention group
Group type: EXPERIMENTAL
Intervention: Women vs Men
Number of subjects: 851
Study 31486377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediators of highest pain in women vs men
Number of subjects: 851
Study 31487218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks
Number of subjects: 24
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dengue infections caused by DENV-1 and/or DENV-2
Number of subjects: 342
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute chikungunya infections
Number of subjects: 342
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Past dengue infections
Number of subjects: 342
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Past chikungunya infections
Number of subjects: 342
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria Rapid Diagnostic Test
Number of subjects: 342
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Number of subjects: 342
Study 31487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial treatment
Number of subjects: 342
Study 31487564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering therapy
Number of subjects: 1900
Study 31487564 — intervention group
Group type: COMPARATOR
Intervention: Prior ASCVD
Number of subjects: 1900
Study 31487564 — intervention group
Group type: COMPARATOR
Intervention: Markers of FH severity and conventional ASCVD risk factors
Number of subjects: 1900
Study 31488093 — intervention group
Group type: EXPERIMENTAL
Intervention: MEG3 rs10132552
Number of subjects: 144
Study 31488093 — intervention group
Group type: EXPERIMENTAL
Intervention: rs10132552 TC + CC
Number of subjects: 144
Study 31488093 — intervention group
Group type: EXPERIMENTAL
Intervention: rs941576 AG + GG
Number of subjects: 144
Study 31488093 — intervention group
Group type: EXPERIMENTAL
Intervention: MEG3 rs7158663
Number of subjects: 144
Study 31488170 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered intervention focusing on improving quality of family planning services, including counseling.
Number of subjects: 0
Study 31488170 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 0
Study 31488216 — intervention group
Group type: EXPERIMENTAL
Intervention: HuMax-IL8 (BMS-986253) administered IV every 2 weeks at doses of 4, 8, 16, or 32 mg/kg
Number of subjects: 15
Study 31488216 — intervention group
Group type: EXPERIMENTAL
Intervention: HuMax-IL8 (BMS-986253) administered IV every 2 weeks
Number of subjects: 15
Study 31488227 — intervention group
Group type: EXPERIMENTAL
Intervention: RESOLVE plus treatment as usual (TAU)
Number of subjects: 40
Study 31488227 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study 31488469 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum haemorrhage (PPH) management according to French guidelines, assessed through various self-completed questionnaires including PDPSI, STAI-Y-A, STAI-Y-B, M.I.N.I. 5.0.0, EPDS, GAD-7, IES-R.
Number of subjects: 1542
Study 31488469 — intervention group
Group type: COMPARATOR
Intervention: Women without PPH (unexposed)
Number of subjects: 1542
Study 31488473 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported preventive measures and management strategies for knee symptoms (including non-pharmacological treatments and CAM)
Number of subjects: 0
Study 31488473 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of healthcare system and surgical procedures
Number of subjects: 0
Study 31489199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-3 criteria
Number of subjects: 1081
Study 31489199 — intervention group
Group type: COMPARATOR
Intervention: MARS-sepsis criteria
Number of subjects: 1081
Study 31489199 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-acquired infection
Number of subjects: 1081
Study 31489199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality for MARS-sepsis criteria
Number of subjects: 1081
Study 31489199 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality for sepsis-3 criteria
Number of subjects: 1081
Study 31490268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg bid)
Number of subjects: 851
Study 31490308 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid with lidocaine, injected with a blunt-tip microcannula
Number of subjects: 60
Study 31491565 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial medial meniscectomy
Number of subjects: 56
Study 31491565 — intervention group
Group type: COMPARATOR
Intervention: Medial meniscus repair
Number of subjects: 56
Study 31491565 — intervention group
Group type: COMPARATOR
Intervention: No medial meniscus involvement
Number of subjects: 56
Study 31491604 — intervention group
Group type: COMPARATOR
Intervention: Primary tumours
Number of subjects: 57
Study 31491604 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic tumours
Number of subjects: 57
Study 31491604 — intervention group
Group type: EXPERIMENTAL
Intervention: CS conversion
Number of subjects: 57
Study 31491604 — intervention group
Group type: EXPERIMENTAL
Intervention: IS conversion
Number of subjects: 57
Study 31491604 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-converted metastases
Number of subjects: 57
Study 31491604 — intervention group
Group type: EXPERIMENTAL
Intervention: IS-converted metastases
Number of subjects: 57
Study 31491604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone receptor-positive and HER2-positive tumours
Number of subjects: 57
Study 31492151 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work intervention recommended for 40% of patients after in-depth analysis
Number of subjects: 57
Study 31492151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikolaus-score (social situation)
Number of subjects: 57
Study 31492151 — intervention group
Group type: COMPARATOR
Intervention: Professional social support
Number of subjects: 57
Study 31492151 — intervention group
Group type: COMPARATOR
Intervention: Long-term support after discharge
Number of subjects: 57
Study 31492151 — intervention group
Group type: COMPARATOR
Intervention: Unmet needs in long-term aftercare
Number of subjects: 57
Study 31492456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 110
Study 31492456 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 110
Study 31492456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phase angle
Number of subjects: 110
Study 31492778 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression or anxiety status evaluated with Patient Health Questionnaire-9 or Generalised Anxiety Disorder-7 Assessment scales during follow-up.
Number of subjects: 5000
Study 31492778 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepression or antianxiety treatment among patients with ACS who received treatment after PCI.
Number of subjects: 5000
Study 31492791 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention programme including a computerized triage algorithm, waiting room patient call system, signage, educational messages, presence of a mediator, and video surveillance.
Number of subjects: 22107
Study 31492791 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention programme implemented in the first month of the intervention period.
Number of subjects: 22107
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSDs for ≥4 weeks
Number of subjects: 246
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 75-84
Number of subjects: 246
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥85
Number of subjects: 246
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 246
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 246
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary education
Number of subjects: 246
Study 31492795 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent use of ≥2 CNSDs
Number of subjects: 246
Study 31492798 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic back muscle strength
Number of subjects: 120
Study 31492798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar paraspinal muscle quantity and quality
Number of subjects: 120
Study 31492798 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional sarcopenic indices
Number of subjects: 120
Study 31492798 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal sagittal balance
Number of subjects: 120
Study 31492798 — intervention group
Group type: EXPERIMENTAL
Intervention: Back performance scale
Number of subjects: 120
Study 31492798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorenson test
Number of subjects: 120
Study 31492988 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU-based combination chemotherapy
Number of subjects: 3223
Study 31493051 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected Mesh (IM) group
Number of subjects: 80
Study 31493051 — intervention group
Group type: COMPARATOR
Intervention: Clean Control (CC) group
Number of subjects: 80
Study 31493163 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks
Number of subjects: 181
Study 31493238 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAs
Number of subjects: 247
Study 31493238 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno and expanded-Baveno criteria
Number of subjects: 247
Study 31493319 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 160
Study 31493319 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart band
Number of subjects: 160